Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Journal of Clinical Virology

Volumn 70, Issue , 2015, Pages 120-127

  Theys, Kristof ^a   Abecasis, Ana ^b   Libin, Pieter ^a,c   Gomes, Perpétua ^d,e   Cabanas, Joaquim ^d   Camacho, Ricardo J ^a   Van Laethem, Kristel ^a,f  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d Centro Hospitalar de Lisboa Ocidental   (Portugal)

^e INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Dolutegravir; HIV 1; Integrase; Interpretation; Resistance; Treatment

Indexed keywords

DOLUTEGRAVIR; INTEGRASE INHIBITOR; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS;

ARTICLE; DRUG ACTIVITY; DRUG TREATMENT FAILURE; EUROPEAN MEDICINES AGENCY; EXPERT SYSTEM; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; MAJOR CLINICAL STUDY; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNCERTAINTY; ANTIVIRAL RESISTANCE; CLINICAL DECISION MAKING; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MUTATION; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

CLINICAL DECISION-MAKING; DRUG PRESCRIPTIONS; DRUG RESISTANCE, VIRAL; GENOTYPE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84939622757     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.07.311     Document Type: Article

References (35)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at AdolescentGL.pdf [Accessed at January 10th 2015]. http://aidsinfo.nih.gov/ContentFiles/Adultand.
2. European AIDS Clinical Society (EACS) Guidelines 7.1 Available at [Accessed at January 10th 2015]. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
3. Tivicay US. prescribing information. (August 2013). drugsatfda_docs/label/ 2013/204790lbl.pdf. [Accessed June 2014]. http://www.accessdata.fda.gov/.
4. Tivicay -EMEA/H/C/002753-EPAR product information. (February 2014) Annex I: Summary of product characteristics pdf. Accessed June 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002753/WC500160680.
5. Kobayashi M., Yoshinaga T., Seki T., Wakasa-Morimoto C., Brown K.W., Ferris R., et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011, 55:813-821.
6. Canducci F., Ceresola E.R., Boeri E., Spagnuolo V., Cossarini F., Castagna A., et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J. Infect. Dis. 2011, 204:1811-1815.
7. Canducci F., Ceresola E.R., Saita D., Castagna A., Gianotti N., Underwood M., et al. In vitro phenotypes to elvitgravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J. Antimicrob. Chemother. 2013, 68:2525-2532.
8. Abram M.E., Hluhanich R.M., Goodman D.D., Andreatta K.N., Margot N.A., Ye L., et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 2013, 57:2654-2663.
9. Eron J.J., Clotet B., Durant J., Katlama C., Kumar P., Lazzarin A., et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J. Infect. Dis. 2013, 207:740-748.
10. Castagna A., Maggiolo F., Penco G., Wright D., Mills A., Grossberg R., et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J. Infect. Dis. 2014, 210:354-362.
11. Akil B., Blick G., Hagins D.P., Ramgopal M.N., Richmond G.J., Samuel R.M., et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING -4, a randomized study. Antivir Ther. 2014, Epub ahead of print.
12. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008, 52:1351-1358.
13. Canducci F., Sampaolo M., Marinozzi M.C., Boeri E., Spagnuolo V., Galli A., et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009, 23:455-460.
14. Sichtig N., Sierra S., Kaiser R., Däumer M., Reuter S., Schülter E., et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009, 64:25-32.
15. Garrido C., Soriano V., Geretti A.M., Zahonero N., Garcia S., Booth C., et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-impact of HIV subtypes and prior raltegravir experience. Antiviral Res. 2011, 90:164-167.
16. Malet I., Fourati S., Charpentier C., Morand-Joubert L., Armenia D., Wirden M., et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J. Antimicrob. Chemother. 2011, 66:2827-2830.
17. Quashie P.K., Mesplède T., Han Y.S., Oliveira M., Singhroy D.N., Fujiwara T., et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J. Virol. 2012, 86:2696-2705.
18. Quashie P.K., Mesplède T., Han Y.S., Veres T., Osman N., Hassounah S., et al. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob. Agents Chemother. 2013, 57:6223-6235.
19. Hardy I., Brenner B., Quashie P., Thomas R., Petropoulos C., Huang W., et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N 155H and multiclass drug resistance. J. Antimicrob. Chemother. 2014, Epub ahead of print.
20. Malet I., Gimferrer Arriaga L., Artese A., Costa G., Parrotta L., Alcaro, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J. Antimicrob. Chemother. 2014, 69:2118-2122.
21. Libin P., Beheydt G., Deforche K., Imbrechts S., Ferreira F., Van Laethem K., et al. RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics 2013, 29:1477-1480.
22. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31:298-303.
23. Pineda-Peña A.C., Faria N.R., Imbrechts S., Libin P., Abecasis A.B., Deforche K., et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect. Genet. Evol. 2013, 19:337-348.
24. Wensing A.M., Calvez V., Günthard H.F., Johnson V.A., Paredes R., Pillay D., et al. Update of the drug resistance mutations in HIV-1. Top Antivir Med 2014, 22:642-650.
25. Meynard J.L., Vray M., Morand-Joubert L., Race E., Descamps D., Peytavin G., et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16:727-736.
26. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42:1608-1618.
27. Vercauteren J., Beheydt G., Prosperi M., Libin P., Imbrechts S., Camacho R., et al. Clinical evaluation of Rega: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS ONE 2013, 8:e61436. 8.
28. ISENTRESS US. prescribing information. (February 2011). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022145s018lbl.pdf.
29. STRIBILD US. prescribing information. (August 2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203100s000lbl.pdf.
30. Rhee S.Y., Liu T.F., Kiuchi M., Zioni R., Gifford R.J., Holmes S.P., et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74.
31. Hurt C.B., Sebastian J., Hicks C.B., Eron J.J. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014, 58:423-431.
32. R Development Core Team: R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2011.
33. Tang M.V., Shafer HIV-1 antiretroviral resistance scientific principles and clinical applications. Drugs 2012, 72:e1-25.
34. Cahn P., Pozniak A.L., Mingrone H., Shuldyakov A., Brites C., Andrade-Villanueva J.F., et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 4results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013, 382:700-708.
35. Piralla A., Paolucci S., Gulminetti R., Comolli G., Baldanti F. HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virology Journal 2011, 8:149.